The approvals of tafamidis (Vyndamax) and tafamidis meglumine (Vyndaqel) in 2019 were a victory for patients with transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). These new agents slow the development of heart failure and reduce the 30-month mortality rate from 43% to 30%. But at $225,000 a year, the drugs may be unaffordable for many. Medicare Part D […]
To continue reading this article or issue you must be a paid subscriber. Sign in
Subscribe to Heart Advisor
Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!